Prelude Therapeutics Incorporated
General ticker "PRLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $119.4M (TTM average)
Prelude Therapeutics Incorporated follows the US Stock Market performance with the rate: 49.4%.
Estimated limits based on current volatility of 3.7%: low 4.03$, high 4.34$
Factors to consider:
- Total employees count: 79 (-39.7%) as of 2025
- Top business risk factors: Operational and conduct risks, Operating losses, Funding requirements, Clinical trial failure, Regulatory and compliance
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.55$, 4.53$]
- 2026-12-31 to 2027-12-31 estimated range: [1.29$, 3.75$]
Financial Metrics affecting the PRLD estimates:
- Positive: with PPE of -1.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 29.16 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 42.57 < Shareholder equity ratio, % of 48.57 <= 64.23
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term PRLD quotes
Long-term PRLD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $7.00MM | $12.14MM |
| Operating Expenses | $132.28MM | $146.71MM | $116.71MM |
| Operating Income | $-132.28MM | $-139.71MM | $-104.57MM |
| Non-Operating Income | $10.45MM | $12.54MM | $5.07MM |
| R&D Expense | $103.39MM | $118.00MM | $94.30MM |
| Income(Loss) | $-121.83MM | $-127.17MM | $-99.50MM |
| Net Income(Loss)* | $-121.83MM | $-127.17MM | $-99.50MM |
| Stockholders Equity | $237.09MM | $131.46MM | $68.64MM |
| Assets | $277.67MM | $175.51MM | $141.31MM |
| Operating Cash Flow | $-107.06MM | $-102.89MM | $-56.30MM |
| Capital expenditure | $3.51MM | $0.76MM | $0.07MM |
| Investing Cash Flow | $-34.65MM | $90.19MM | $53.46MM |
| Financing Cash Flow | $136.40MM | $-0.12MM | $24.82MM |
| Earnings Per Share** | $-2.02 | $-1.68 | $-1.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.